A systematic review on donepezil-based derivatives as potential cholinesterase inhibitors for Alzheimer's disease.

Article Details

Citation
Copy to clipboard

Korabecny J, Spilovska K, Mezeiova E, Benek O, Juza R, Kaping D, Soukup O

A systematic review on donepezil-based derivatives as potential cholinesterase inhibitors for Alzheimer's disease.

Curr Med Chem. 2018 May 16. pii: CMC-EPUB-90497. doi: 10.2174/0929867325666180517094023.

PubMed ID
29768996 [ View in PubMed
]
Abstract

Alzheimer's disease (AD) is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual deterioration of intellectual capacity. Its etiology has not been elucidated yet. To date, only one therapeutic approach has been approved for the treatment of AD. The pharmacotherapy of AD has relied on non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist - memantine, and acetylcholinesterase (AChE) inhibitors (AChEIs) - tacrine, donepezil, rivastigmine and galantamine. Donepezil was able to ameliorate the symptoms related to AD mainly via AChE, but also through reduction of beta-amyloid burden. This review presents the overview of donepezil-related compounds as potential anti-AD drugs developed on the basis of cholinergic hypothesis to act as solely AChE and butyrylcholinesterase (BChE) inhibitors.

DrugBank Data that Cites this Article

Drugs